Dendreon Articles
Zytiga overtaking Provenge in MCRPC
17 January 2012
Dendreon upbeat on Provenge sales
8 January 2012
Dendreon cashes in Victrelis royalty
8 December 2011
NWBT highlights cost effectiveness of DCVax in view of recent immunotherapy pricing concerns
11 August 2011
Dendreon scales back Provenge sales forecast; 2nd-qtr 2011 net revenue climbs to $49.6 million
5 August 2011
Dendreon shares rise on plans to gain EU marketing approval for Provenge and US commercialization
10 January 2011
US MEDAC panel review backs Dendreon’s prostate cancer drug efficacy Provenge for Medicare
18 November 2010
USA’s Medicare review of Dendreon’s prostate cancer vaccine Provenge renews medical cost-benefit debate, says Washington Post
10 November 2010
Major turnaround for Dendreon as US FDA approves Provenge for advanced prostate cancer
30 April 2010
Showing 1-25 of 25 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
